Outcomes of Severely Obese Patients Supported by a Centrifugal-Flow Left Ventricular Assist Device

With advancements in technology leading to improvements in survival as well as quality of life,1,2 left ventricular assist devices (LVADs) are increasingly used to support patients with end-stage heart failure as either a bridge to cardiac transplantation (BTT) or as destination therapy (DT). Concurrent with the epidemic of heart failure,3 is also the problem of obesity which is present in greater than one third of U.S. adults when defined as a body mass index [BMI]> 30 kg/m2. Obesity is a risk factor for the development of heart failure4 and many obese patients will progress to end-stage disease requiring evaluation for cardiac transplantation and LVAD therapy.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Source Type: research

Related Links:

This study aims to determine if there is an association between higher BMI and exchange-free survival at one year post LVAD implantation.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: 461 Source Type: research
Background: Obesity is an epidemic closely associated with heart failure. The definitive treatment for end-stage heart failure is cardiac transplantation. However, morbid obesity is a contraindication for cardiac transplant listing. Left ventricular assist devices (LVADs) have emerged as a bridge to transplant for heart failure patients, and bariatric surgery can be performed in patients with LVADs. The effect of weight loss on cardiac function for these patients is not well known.
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Source Type: research
Obesity is an epidemic that is progressive, costly, and closely associated with cardiac disease and death. Obesity causes structural and functional changes in the heart due to increases in metabolic demand, total blood volume, and stroke volume, all of which cause left ventricular dilation, cardiac muscle hypertrophy, and atrial enlargement [1,2]. Heart failure is a deadly condition, affecting up to 5.8 million people in the United States with associated health care costs exceeding 30 billion dollars per year [3,4].
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Abstract Heart failure with preserved ejection fraction (HFpEF) is now an emerging cardiovascular epidemic, being identified as the main phenotype observed in clinical practice. It is more associated with female gender, advanced age and comorbidities such as hypertension, diabetes, obesity and chronic kidney disease. Amyloidosis is a clinical disorder characterized by the deposition of aggregates of insoluble fibrils originating from proteins that exhibit anomalous folding. Recently, pictures of senile amyloidosis have been described in patients with HFpEF, demonstrating the need for clinical cardiologists to investigate t...
Source: Arquivos Brasileiros de Cardiologia - Category: Cardiology Source Type: research
Abstract Heart failure with preserved ejection fraction (HFpEF) is now an emerging cardiovascular epidemic, being identified as the main phenotype observed in clinical practice. It is more associated with female gender, advanced age and comorbidities such as hypertension, diabetes, obesity and chronic kidney disease. Amyloidosis is a clinical disorder characterized by the deposition of aggregates of insoluble fibrils originating from proteins that exhibit anomalous folding. Recently, pictures of senile amyloidosis have been described in patients with HFpEF, demonstrating the need for clinical cardiologists to investigate t...
Source: Arquivos Brasileiros de Cardiologia - Category: Cardiology Source Type: research
Abstract Heart failure with preserved ejection fraction (HFpEF) is now an emerging cardiovascular epidemic, being identified as the main phenotype observed in clinical practice. It is more associated with female gender, advanced age and comorbidities such as hypertension, diabetes, obesity and chronic kidney disease. Amyloidosis is a clinical disorder characterized by the deposition of aggregates of insoluble fibrils originating from proteins that exhibit anomalous folding. Recently, pictures of senile amyloidosis have been described in patients with HFpEF, demonstrating the need for clinical cardiologists to investigate t...
Source: Arquivos Brasileiros de Cardiologia - Category: Cardiology Source Type: research
Abstract Heart failure with preserved ejection fraction (HFpEF) is now an emerging cardiovascular epidemic, being identified as the main phenotype observed in clinical practice. It is more associated with female gender, advanced age and comorbidities such as hypertension, diabetes, obesity and chronic kidney disease. Amyloidosis is a clinical disorder characterized by the deposition of aggregates of insoluble fibrils originating from proteins that exhibit anomalous folding. Recently, pictures of senile amyloidosis have been described in patients with HFpEF, demonstrating the need for clinical cardiologists to investigate t...
Source: Arquivos Brasileiros de Cardiologia - Category: Cardiology Source Type: research
Introduction: Strong association between obesity and adverse cardiovascular outcomes have been previously reported. Chronic inflammation and venous stasis appear to be major effector mechanisms leading to increased risk of thrombosis, bleeding and infection in obese patients. With obesity as a relative contraindication to heart transplantation and the growing obesity epidemic, increasing number of obese heart failure patients are being evaluated for Left Ventricular Assist Devices (LVAD). The influence of varying body mass index (BMI) and inflammation on the risk of adverse outcomes is not yet understood.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Source Type: research
More News: Cardiology | Eating Disorders & Weight Management | Epidemics | Epidemiology | Heart | Heart Failure | Heart Transplant | Obesity | Transplants